Filing Details
- Accession Number:
- 0001127602-24-016164
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-21 17:46:36
- Reporting Period:
- 2024-05-17
- Accepted Time:
- 2024-05-21 17:46:36
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 313143 | Haemonetics Corp | HAE | Surgical & Medical Instruments & Apparatus (3841) | 042882273 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1699629 | L Michelle Basil | 125 Summer Street Boston MA 02110 | Evp And General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-05-17 | 1,073 | $95.00 | 29,352 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-05-17 | 669 | $95.73 | 28,683 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2024-05-17 | 4,178 | $0.00 | 32,861 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2024-05-20 | 1,604 | $95.08 | 31,257 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-qualified Stock Option (Right to Buy) | Acquisiton | 2024-05-17 | 9,183 | $0.00 | 9,183 | $95.73 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 9,183 | 2031-05-17 | No | 4 | A | Direct |
Footnotes
- Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).
- This number includes unvested restricted stock units ("RSUs") previously reported.
- Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
- The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
- Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
- Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.
Billionaire Hedge Funds
